688656 Hob Biotech Group Corp., Ltd
- 137.00
- -8.00-5.52%
Hob Biotech Group Corp., Ltd News
Haoubo (688656) 2024 semi-annual report review: Steady growth in performance, new desensitizing drug business is worth looking forward to
Haoubo (688656): Revenue increased 23%, deployed desensitizing drugs to create a fully closed-loop service for precise treatment
Haoobo (688656): Performance meets expectations, B2C business accelerates layout
Haoobo (688656) 2023 Third Quarter Report Review: Performance growth is in line with expectations, desensitization treatment is worth looking forward to
Haoobo (688656): The 52% recovery in performance in the post-pandemic era benefited from increased profitability of large-scale production
Haoobo (688656): Many products have received EU CE certification, and overseas markets are worth looking forward to
Hao Obo (688656) three-quarter report comments: accelerated performance recovery of long-term development is worth looking forward to
Haoobo (688656) 2021 Interim Report Review: Performance is in line with our expectations and optimistic about the company's medium- to long-term development
Hao Oobo (688656): the performance is growing rapidly and the long-term development is worth looking forward to.
Haoobo (688656): There is broad scope for long-term development of allergy testing leaders
Hao Obo (688656) Quarterly report 2021 comments: the performance is in line with our expected layout allergy + autoimmune double track has a broad space for long-term growth.
Hao Oobo (688656) 2020 Annual report comment: the performance is in line with our expected epidemic situation and does not change the company's medium-and long-term development logic.
Haoobo (688656): The number of “allergy and self-free” high-quality racetracks is growing rapidly
Haoobo (688656): Leading allergy testing self-exemption business is growing rapidly
Analysis
Price Target
No Data
No Data